Stock Ratings / Health Care / EIKN / forecast

SABS (37) CABA (33) IPSC (18) AGEN (30) ⌘ Pro Terminal →

Eikon Therapeutics Inc. (EIKN) 12-Month Stock Forecast & Price Target Cone

Q: What is EIKN's 12-month stock price target?

Eikon Therapeutics Inc. (EIKN) carries a 12-month consensus base price target of $4.93 (-7.2% from $5.31), with a bull-case target of $18.27 and a bear-case floor of $3.85.

Q: Is EIKN stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates EIKN D- (Sell — SELL) with an RQD Confidence score of 42/100.

$5.31 -0.75% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.29

Eikon Therapeutics Inc. (EIKN) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $289.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EIKN Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EIKN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Eikon Therapeutics Inc. (NASDAQ: EIKN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $5.31 (-0.75% 1D, market cap $289.8M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 9/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EIKN compare to SABS and CABA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EIKN carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SABS (SAB Biotherapeutics Inc.) holds a D- grade (37/100 RQD, P/E 22.1x, ROIC -27.4%, cap $293.9M) and CABA (Cabaletta Bio Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $268.7M). Among the 5-stock peer group, SABS leads on earnings multiple (22.1x) while IPSC leads on capital efficiency (-14.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EIKN?

▼

Per EIKN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001861123), Eikon Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $594.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.29 (-0.33%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EIKN)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY EIKN SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0.2% FCF Margin ($8.1M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$7.26+6.1% Next Q

Q2 (-2Q)

Grade D$7.70-28.1% Next Q

Q3 (-1Q)

Grade D$5.54-4.2% Next Q

Current

Grade D-$5.31-7% Hist 90D α

Trajectory: C- (50) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a EIKN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While EIKN currently carries a cautious 42/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.47) and Max Pain ($5.58) forces dealer call-delta covering toward $18.27.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EIKN• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EIKN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your EIKN Position Size: $10,000

Shares at $5.31: 1883.2 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $3.85

$7,250

$-2,750 (-27.5%)

12M Consensus BaseTarget $4.93

$9,284

$-716 (-7.2%)

12M Bull Case BreakoutTarget $18.27

$34,407

+$24,407 (+244.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$5	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$17	69%	B
JP MorganUS Large-Cap Research	SELL	$4	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EIKN)

✓Walkthrough of EIKN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EIKN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -48.30%▼ SUPPORT BREAKDOWN

2026-11-02O $5.54H $5.54L $5.31C $5.31VOL 575.8K

RES: $15.31SUP: $5.93SMA50: $8.47SMA200: $10.40

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EIKN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EIKN Butterfly Map → + Track EIKN →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on EIKN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EIKN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EIKN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EIKN)

Health Care Rank #473 of 1016 ⚔️ SABS vs EIKN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EIKN vs. SABS, CABA, IPSC, AGEN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Eikon Therapeutics Inc. (EIKN) ranks #473 by composite RQD confidence (42/100, grade D-) and #523 by equity capitalization ($289.8M). Within this direct 5-issuer industry benchmark cohort, SABS leads on earnings valuation at 22.1x trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. EIKN currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EIKN ACTIVE Eikon Therapeutics Inc.	D-	42/100	—	—	—	-0.75%	$289.8M	Benchmark Subject
SABS SAB Biotherapeutics Inc.	D-	37/100	22.1x	—	-27.4%	+3.72%	$293.9M	/sabs-vs-eikn →
CABA Cabaletta Bio Inc.	E	33/100	—	—	-35.0%	-4.73%	$268.7M	/caba-vs-eikn →
IPSC Century Therapeutics Inc.	E	18/100	—	—	-14.1%	+0.69%	$264.4M	/ipsc-vs-eikn →
AGEN Agenus Inc.	E	30/100	—	96.0%	-35.0%	-3.53%	$320.2M	/agen-vs-eikn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001861123

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eikon Therapeutics Inc. (EIKN) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, EIKN closed FY2025 with $594.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$594.7M	—

3. EIKN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EIKN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does EIKN compare to SABS and CABA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for EIKN?

Where is EIKN trading relative to its 50-day, 200-day, and 52-week technical levels?

EIKN last traded at $5.31 (-0.75% on volume of 553,138 shares), positioning the stock -37.31% below its 50-day simple moving average ($8.47) and -48.94% below its 200-day simple moving average ($10.40). Across its 52-week range of $5.01 to $17.40, EIKN sits at the 2.4% percentile with a 14-day RSI of 28.8 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($4.65 to $5.97).

EIKN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is EIKN's 12-month stock price target?

Eikon Therapeutics Inc. (EIKN) carries a 12-month consensus base price target of $4.93 (-7.2% from $5.31), with a bull-case target of $18.27 and a bear-case floor of $3.85.

Is EIKN stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates EIKN D- (Sell — SELL) with an RQD Confidence score of 42/100.

Direct Sub-Reports: EIKN RQD Cockpit EIKN 12M Forecast EIKN Earnings & Move EIKN Dividends & DRIP EIKN Insiders & 13F EIKN Whale Options EIKN Profit Sankey EIKN News & Why

ROARABLE RATING BRIEF • RQD 42/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

EIKN — Eikon Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:16:52Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, EIKN scores 42 out of 100 and carries a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars break down as follows:

Fundamental Cash Engine: 10 / 20 (ROIC 0%; FCF yield 0%). The cash-generation pillar is weak because the source data shows no reported return on invested capital and no free-cash-flow yield.
Whale 13F Flow: 3 / 20 (institutional accumulation and options positioning). This is the lowest pillar score, indicating weak institutional support in the rating's view. The holders section contains no 13F detail to explain the score.
Insider Conviction: 9 / 20 (SEC Form 4 and Congressional PTR cluster flow). The score is below midpoint; the source data contains no insider transaction detail to explain it.
Macro Regime Fit: 7 / 20 (beta 1.0; sector sensitivity). The beta of 1.0 is market-equivalent, and the rating assigns limited credit for regime fit.
Forensic Balance Sheet: 13 / 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). This is the strongest pillar, with moderate balance-sheet metrics.

For a prospective investor, the practical implication is that the rating's weakest inputs are cash generation and institutional flow, while the balance sheet is the relatively stronger leg. The source data reports no revenue, no operating income, and no net income for FY 2025, so the cash-engine score rests on absent earnings rather than on measured losses. Valuation cannot be assessed on earnings multiples because P/E and EV/EBITDA are unavailable. The rating does not state its methodology beyond the pillar labels, so the weighting of each input is not verifiable from the source data.

Business

Eikon Therapeutics Inc. is listed on NASDAQ and classified under the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company is a NASDAQ-listed issuer with a market capitalization of $0.3B. The source data does not describe its products, customers, or revenue model. Recent news items reference clinical-stage oncology programs, including an EIK1001 update, PARP1-selective and WRN helicase programs, and a prostate cancer drug candidate filed with the FDA, but the source data does not establish how these generate revenue.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025 (filed 2025-12-31)	$0.0M	$0.0M	$0.0M	N/A	N/A	$104.9M	N/A

Per the SEC financials, FY 2025 reports $0.0M in revenue, operating income, and net income, with cash of $104.9M. Gross, operating, and net margins are each reported as 0%, and ROIC is 0%. The Roarable RQD rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5, which together describe a balance sheet with moderate forensic strength despite the absence of reported earnings. Debt is listed as N/A in the SEC financials, so the 0.5 Debt/Equity figure cannot be reconciled to a reported debt amount within this dataset.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, the feed contains six items, each tagged with a relative-time marker:

Estimates coverage (TradingView, YELLOW, market wire): a general estimates report with no specific figures in the summary.
EIK1001 update (Yahoo Finance, YELLOW): an updated EIK1001 data presentation from the TeLuRide-005 study at the European Society for Medical Oncology Congress.
Prostate cancer candidate filing (Stock Titan, YELLOW): a report that a prostate cancer drug candidate targeting treatment-resistance variants has been filed with the FDA.
Analyst initiation (MarketBeat, YELLOW): a "Buy" rating in new coverage at HC Wainwright.
Growth-positioning analysis (Simply Wall St, GREEN, catalyst): a general article on whether the company is positioned for growth.
PARP1-selective and WRN helicase data (Yahoo Finance, YELLOW): data presented at the same ESMO Congress.

Per the Butterfly Supply-Chain Graph, the proprietary liquidity signal is a LIQUIDITY_TAILWIND with a terminal label of MACRO TAILWIND SCORE (18/100), severity 94, and direction BEARISH. The signal reports a 4.27x net-liquidity beta with a correlation of r = +0.18 over a rolling five-year regression, and it cites a True Net Liquidity Index of $5,745.73B with a -0.64% four-week rate of change and High-Yield OAS of +2 bps. Per the same graph, these liquidity conditions weigh on the stock because of its elevated sensitivity to net liquidity conditions.

Watch items: the bearish liquidity signal, the zero reported revenue, and the absence of analyst price targets. Catalysts: the clinical data presentations and the FDA filing referenced in news items.

Open Questions

What does the company sell, and is any revenue expected? The FY 2025 SEC financials report $0.0M in revenue, which the source data does not explain.
What is the cash runway implied by $104.9M in cash against an absent debt figure and zero operating income?
How were the Whale 13F Flow (3/20) and Insider Conviction (9/20) pillar scores derived, given that the holders section contains no ownership data?
What is the status and timeline of the FDA filing and clinical programs referenced in recent news, and what regulatory or trial milestones are scheduled?
What explains the 0.5 Debt/Equity ratio when the SEC financials report debt as N/A?

EIKN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Eikon Therapeutics Inc. (EIKN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EIKN Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 9h ago

Eikon Therapeutics, Inc. Estimates – NASDAQ:EIKN

TradingView report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 12h ago

Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress

Yahoo Finance report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 15h ago

A prostate cancer drug candidate targets variants tied to treatment resistance. Eikon filed it with the FDA.

Stock Titan report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 18h ago

Eikon Therapeutics (NASDAQ:EIKN) Stock Rated "Buy" in New Coverage at HC Wainwright

MarketBeat report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Simply Wall St • 21h ago

Is Eikon Therapeutics (NASDAQ:EIKN) In A Good Position To Invest In Growth?

Simply Wall St report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress

Yahoo Finance report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

HC Wainwright & Co. initiates coverage of Eikon Therapeutics with Buy rating, $23 price target

TradingView report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Eikon Therapeutics, Inc. $EIKN Shares Newly Bought by Regents of The University of California

MarketBeat report covering Eikon Therapeutics Inc. (EIKN) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EIKN Bull vs. Bear Conversation Board — What's Your Call at $5.31?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EIKN 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $4.71 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is EIKN (D- • RQD 42/100) a Buy at $5.35?

Welcome to the EIKN (Eikon Therapeutics Inc.) Roar Pit. Current RQD Composite is 42/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $4.01 (-25.0%)

Spot @ $5.35

Pump the brakes on EIKN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on EIKN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Eikon Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $6.85 (+28.0%)

Spot @ $5.35

EIKN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on EIKN, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $5.35 (52-wk range $5.01 - $17.40), any beat on forward guidance forces shorts and underweight funds to chase.